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How neoplastic cells respond to therapy is not solely dependent on the complexity of the genomic aberra-
tions they harbor but is also regulated by numerous dynamic properties of the tumormicroenvironment. Iden-
tifying and targeting critical pathways that improve therapeutic efficacy by bolstering anti-tumor immune
responses holds great potential for improving outcomes and impacting long-term patient survival. Macro-
phages are key regulators of homeostatic tissue and tumor microenvironments. Therefore, therapeutics im-
pacting macrophage presence and/or bioactivity have shown promise in preclinical models and are now
being evaluated in the clinic. This review discusses the molecular/cellular pathways identified so far whereby
macrophages mediate therapeutic responses.Macrophages are represented in all tissues by functionally and
phenotypically distinct resident populations that are critical for
development and homeostasis (Wynn et al., 2013). Under non-
pathological conditions, most resident macrophage populations
derive from embryonic progenitors and are maintained through
local proliferation (Epelman et al., 2014). Exceptions to this
include intestinal, dermal, and alveolar macrophages at barrier
sites (Bain et al., 2014; McGovern et al., 2014; Perdiguero
et al., 2015; Yona et al., 2013) and macrophages in the adult
heart that are replaced by circulating bone marrow-derived
Ly6C+ inflammatory monocytes over a timescale of several
weeks (Molawi et al., 2014). Under pathological conditions, there
is evidence for both local proliferation and recruitment, with dif-
ferences observed by tissue location and type of inflammatory
insult (Epelman et al., 2014).
Solid tumors appear to be unique. Preclinical studies indi-
cate minimal macrophage proliferation and shorter half-lives
compared with resident macrophages in counterpart homeo-
static tissues, measurable in days to weeks (Movahedi et al.,
2010; Strachan et al., 2013). That said, CD68+ cells also positive
for proliferating cell nuclear antigen (PCNA) expression have
been observed in breast cancers, where they are associated
with a poor clinical outcome (Campbell et al., 2011). Whether
the macrophage lifespan in this context is reflecting diminished
tissue integrity and the extent of damage/inflammation or,
instead, represents an adaptive process engaged by tumors to
support growth is unclear, but production of the C-C chemokine
ligand 2 (CCL2) and/or colony-stimulating factor 1 (CSF-1) are
necessary to sustain their numbers (Noy and Pollard, 2014).
With the critical role for CCL2 and CSF-1 in recruiting macro-
phages to neoplastic tissue, there is growing interest in thera-
peutics targeting these ligands and/or their respective receptors
in an effort to ablate the pro-tumorigenic properties of macro-
phages. This therapeutic approach has led to improved out-
comes in a range of pre-clinical models, particularly for agents
targeting CSF-1 or the CSF-1 receptor (CSF-1R), the results of
which have spurred several clinical trials (Table 1).
As monotherapy, CSF-1R inhibition alone impedes the growth
of orthotopically implanted pancreatic ductal adenocarcinoma462 Cancer Cell 27, April 13, 2015 ª2015 Elsevier Inc.(PDAC) cell lines (Mitchem et al., 2013), prevents cervical carci-
nogenesis (Strachan et al., 2013), and induces regression of glio-
blastoma multiforme (GBM) (Pyonteck et al., 2013). In other
tumor models CSF-1R inhibition is without consequence as
monotherapy. However, synergism with other modalities,
including chemotherapy (DeNardo et al., 2011; Mitchem et al.,
2013; Paulus et al., 2006; Ruffell et al., 2014), radiation therapy
(Shiao et al., 2015; Xu et al., 2013), angiogenic inhibitors (Price-
man et al., 2010), adoptive cell transfer (Mok et al., 2014), and
immune checkpoint blockade (Zhu et al., 2014) have been
revealed. Together, these findings implicate macrophages in
regulating therapeutic responses and indicate that durable re-
sponses may be obtained by augmenting standard of care or
emerging therapies with ‘‘macrophage antagonists.’’ This review
focuses on the mechanisms underpinning these observations
and concludes with a discussion of targeting approaches that
extend beyond inhibiting macrophage recruitment.
Clinical Significance of Macrophages
For many solid tumor types, high densities of cells expressing
macrophage-associated markers have generally been found to
be associated with a poor clinical outcome (Figure 1; Komohara
et al., 2014; Zhang et al., 2012). There are conflicting data for
lung, stomach, prostate, and bone, where both positive and
negative outcome associations have been reported (Zhang
et al., 2012), possibly related to the type/stage of cancer evalu-
ated, (e.g., Ewing sarcoma versus osteosarcoma) (Buddingh
et al., 2011; Fujiwara et al., 2011) or to the type of analysis per-
formed (e.g., quantitation of stromal versus intratumoral macro-
phages). Some discrepancy may also reflect the use of different
macrophage markers. CD68, a glycoprotein predominantly resi-
dent in intracellular granules, represents a fairly specific marker
for murine macrophages and, in combination with F4/80, iden-
tifies a majority of tumor-associated macrophages. In humans,
however, CD68 expression is widespread and includes granulo-
cytes, dendritic cells, fibroblasts, endothelial cells, and some
lymphoid subsets (Gottfried et al., 2008; Hameed et al., 1994;
Ruffell et al., 2012b). The use of CD68 for association studies
in this context is therefore of variable utility. A clear example of
Table 1. Macrophage Therapeutic Targeting
Pathway Targeta Efficacy in Murine Models Clinical Compounds Clinical Trials in Solid Tumorsb
Recruitment CD11b radiation, chemotherapy rovelizumab
CSF-1R single agent (GBM, PDAC),
chemotherapy, radiation,
angiogenesis inhibitors
PLX3397, AMG820 NCT01596751 (O); NCT01444404 (C);
NCT01349036 (O); NCT01004861 (O);
NCT01346358 (O); NCT02265536 (O);
NCT01494688 (O); NCT02323191 (O)
IMC-CS4/LY3022855,
RG7155/RO5509554
CCL2 single agent (metastasis,
PDAC)
carlumab NCT00992186 (C); NCT01204996 (C)
Neuropilin-1 angiogenesis inhibitors MNRP1685A NCT00747734 (C); NCT00954642 (C)
ANG2 single agent (mammary),
chemotherapy, angiogenesis
inhibitors
nesvacumab NCT01271972 (O); NCT01688960 (O)
Polarization IL-4 single agent (metastasis),
chemotherapy, radiation
pascolizumab
IL4Ra dupilumab
IL-13 chemotherapy lebrikizumab, tralokinumab,
GSK679586,
FcgR chemotherapy rituximab (CD20), ibrutinib
(BTK), R788 (Syk)
Function IL-6 clazakizumab, olokizumab,
siltuximab, sirukumab
NCT00433446 (C); NCT00385827 (C)
NCT00841191 (C)
IL-6R tocilizumab, sarilumab
TNF-a mitogen-activated protein
kinase inhibitors
adalimumab, certolizumab,
etanercept, golimumab,
infliximab
Activation CD40 single agent (PDAC),
chemotherapy
CP-870,893 NCT00711191 (C); NCT01456585 (C)
NCT02157831 (C); NCT01008527 (O)
NCT02225002 (C); NCT00607048 (C)
NCT01103635 (O)
O, ongoing; C, completed.
aOnly targets with clinical compounds are listed.
bData obtained from https://clinicaltrials.gov.
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phage scavenger receptors CD163 and CD204, but not CD68,
yielded correlations with negative outcome (Chung et al., 2012;
Hirayama et al., 2012; Ohri et al., 2011; Quatromoni and Erusla-
nov, 2012).
In addition to potentially representing more selective macro-
phage biomarkers, both CD163 and CD204 are associated
with activation of macrophages toward an alternative or
tumor-promoting and immunosuppressive phenotype, and,
accordingly, significant correlations between CD163/CD204
and negative outcomes have been reported across multiple tu-
mor types (Komohara et al., 2014). These correlations may indi-
cate that macrophage polarization can direct clinical outcome,
as also supported by the positive association between the pres-
ence of CD68+ cells and survival in colorectal adenocarcinoma
(Roxburgh and McMillan, 2012). Unlike most populations of
tumor-associated macrophages that possess pro-tumor and
immunosuppressive properties (Biswas and Mantovani, 2010),
macrophages in human colorectal cancer have been found to
be functionally (and phenotypically) anti-tumor (Edin et al.,
2012; Ong et al., 2012; Zhang et al., 2014). Together, these
data collectively support the tenet that repolarizing macro-
phages toward an anti-tumor phenotypic state, either byimpeding activities/signals that drive pro-tumor polarization or
by delivering exogenous signals that enhance anti-tumor polar-
ization, could act as an alternative and perhaps more effica-
cious approach to blocking macrophage recruitment, even
though these activities and responses are all dynamically regu-
lated in vivo. Indeed, an agonist monoclonal antibody against
CD40, a co-stimulatory protein found on professional antigen-
presenting cells, has demonstrated efficacy in mouse models
of PDAC (Beatty et al., 2011) and patients with PDAC (Beatty
et al., 2013) when delivered in combination with the chemother-
apeutic agent gemcitabine, ostensibly via the anti-tumor activ-
ities of macrophages (Vonderheide et al., 2013). In addition to
the use of an anti-CSF-1R antibody in diffuse-type giant cell tu-
mors (Ries et al., 2014), these are the first clinical studies to
demonstrate the potential efficacy of macrophage-targeted
agents.
Polarization and Macrophage Function
Macrophages produce an array of cytokines, chemokines, poly-
peptide growth factors, hormones, matrix-remodeling prote-
ases, andmetabolites, many of which possess tumor-promoting
activities (De Palma and Lewis, 2013; Noy and Pollard, 2014;
Ruffell et al., 2012a). A caveat to some of these reportedCancer Cell 27, April 13, 2015 ª2015 Elsevier Inc. 463
Figure 1. Clinical Implications of Macrophage Density
Organs where tumor progression and/or clinical outcome are negatively
associated with increased macrophage density are shown in red. Green in-
dicates a positive association. Organs where the implications of macrophages
density are unclear or unknown are shown in gray and black, respectively.
Image created by Tarot Walker.
Figure 2. Macrophage Polarization as a Dynamic System
The integration of multiple signals emanating from the tumor microenviron-
ment (outer circle) dictates the functional role of macrophages (inner circle).
Integrins and toll-like receptors (TLRs) will be engaged by multiple ligands.
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utilizing neoplastic myeloid cell lines or bone marrow-derived
macrophages and, therefore, cannot account for the complex
milieu of polarization signals to which macrophages would be
exposed in vivo (Figure 2). This includes the aforementioned
CSF-1 and CCL2, prostaglandin E2 (PGE2), and damage-associ-
ated molecular patterns (DAMPs) such as high-mobility group
box 1 protein (HMGB1), extracellular ATP, and degraded extra-
cellular matrix components (Ruffell et al., 2012a; Zelenay and
Reis e Sousa, 2013).
Stabilization of hypoxia-inducible factor (HIF) 1a and 2a is also
important in mediating the pro-tumor properties of macro-
phages, as evidenced by the use of LysM-cre mice to induce
myeloid-specific loss of either factor (Doedens et al., 2010; Im-
tiyaz et al., 2010). As might be expected, hypoxic conditions
drive an angiogenic phenotype in macrophages, and, in vivo,
this occurs specifically in a subpopulation of macrophages
found within hypoxic regions of tumors that express low levels
of major histocompatibility complex (MHC) II (Laoui et al.,
2014; Movahedi et al., 2010). The recruitment of macrophages
(presumably MHCIILO) into hypoxic regions through Neuropilin-
1 also supports an immunosuppressive phenotype (Casazza
et al., 2013) that is likely dependent upon HIF-1a (Doedens
et al., 2010). Surprisingly, however, although hypoxia can induce
HIF-1a-dependent expression of arginase-1 in macrophages
(Doedens et al., 2010), neither improving tumor oxygenation
nor preventing macrophage recruitment into hypoxic areas al-
ters arginase-1 expression (Casazza et al., 2013; Laoui et al.,
2014). This discrepancy might be explained by the recent finding
that lactic acid promotes arginase-1 expression by macro-
phages in an HIF-1a-dependent manner (Colegio et al., 2014).
Finally, the use of immune-competent murine models has
firmly established that macrophage polarization and function464 Cancer Cell 27, April 13, 2015 ª2015 Elsevier Inc.within tumors are strongly influenced by lymphocytes through
the production of multiple factors, including interleukin (IL)-4,
IL-10, IL-13, interferon (IFN)-g, tumor necrosis factor (TNF)-a,
and immunoglobulins (Andreu et al., 2010; DeNardo et al.,
2009; Gocheva et al., 2010; Guiducci et al., 2005; Kang et al.,
2011). These activities include mediating responses to therapy
because B cells coated in anti-CD20 antibody can suppress their
phagocytic removal from circulation by Kupffer cells through the
secretion of IL-10 (Horikawa et al., 2011), whereas B cell produc-
tion of immunoglobulins (Affara et al., 2014) and CD4+ T cell
expression of IL-4 (Shiao et al., 2015) suppress responses to
cytotoxic therapy by altering macrophage polarization. Even
the efficacy of CSF-1R inhibition depends upon altered macro-
phage polarization, rather than depletion, in certain models
(Pyonteck et al., 2013).Macrophage Function and Therapeutic Resistance
Regulation of Tumor Cell Survival Pathways by
Macrophages
The general concept that neoplastic cell-extrinsic factors
mediate resistance to cytotoxic therapy is due to 3D cell culture
models evaluatingmicroenvironmentally derived factors (Correia
and Bissell, 2012), but in vivo studies have revealed that macro-
phages also mediate chemotherapy resistance by providing
survival factors and/or activating anti-apoptotic programs in ma-
lignant cells. Although macrophage-secreted soluble factors
have usually been implicated, it is also possible that extracellular
matrix deposition and/or remodeling or direct cell-cell interac-
tions are involved (Castells et al., 2012; Correia and Bissell,
2012; Meads et al., 2009).
Using a CSF-1-neutralizing antibody in combination with
chemotherapy, Paulus et al. (2006) reported increased
chemosensitivity of subcutaneous MCF-7 breast cancer xeno-
grafts. Co-culture studies utilizing mammary carcinoma cell
lines and bone marrow-derived macrophages revealed
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and etoposide (Shree et al., 2011) and to gemcitabine in murine
PDAC cells (Mitchem et al., 2013). At least with PDAC cells, this
resistance is dependent on the activation of signal transducer
and activator of transcription 3 (STAT3), implicating macro-
phage IL-6 or other macrophage-derived factors such as milk
fat globule-epidermal growth factor VIII, found to promote resis-
tance to carboplatin in vivo and to synergize with IL-6 to
enhance tumor cell growth (Jinushi et al., 2011). STAT3 activa-
tion promotes neoplastic cell proliferation and survival, and mul-
tiple tumor cell lines exhibit IL-6- or STAT3-dependent chemore-
sistance in vitro (Taniguchi and Karin, 2014; Yu et al., 2014).
Although autocrine production of IL-6 is common, tumor-asso-
ciated macrophages produce IL-6 in vivo (DeNardo et al.,
2009; Movahedi et al., 2010; Song et al., 2009), with expression
induced in bone marrow-derived macrophages by co-culture
with neoplastic cells (Mitchem et al., 2013). However, because
the only in vivo evidence of IL-6 being chemoprotective derives
from a murine lymphoma model where IL-6 is expressed by
thymic endothelial cells (Gilbert and Hemann, 2010), the source
and relevance of IL-6 during chemotherapy for solid tumors re-
mains incompletely described.
Surprisingly, macrophage production of soluble chemopro-
tective factors is in part dependent on cathepsin protease activ-
ity, specifically cathepsin B and S, where inhibition of cathepsin
activity in vivo enhances the response of mammary carcinomas
to paclitaxel (Shree et al., 2011). A possible underlying mecha-
nism may derive from the cathepsin B-dependent activation of
inflammasomes in myeloid cells following treatment with gemci-
tabine or fluorouracil, leading to IL-1b release and enhancement
of a TH17 immune response (Bruchard et al., 2013). Tumor-asso-
ciated macrophages isolated from ovarian cancer patients also
direct IL-17 production in memory T cells through IL-1b and IL-
23 production (Kryczek et al., 2009). Because IL-17 induces
IL-6 expression in multiple cell types, including melanoma,
mesenchymal, endothelial, and immune cells (Wang et al.,
2009), cathepsin B could, therefore, be linked indirectly to
STAT3 activation. However, IL-17 has also been found to direct
anti-tumor responses to subcutaneously implanted tumor cell
lines following treatment with anthracycline chemotherapy (Ma
et al., 2011), and a role for IL-17 fails to explain macrophage che-
moprotection in the absence of T cells. A more direct pathway
may be through IL-1b-induced IL-6 expression, which occurs
in multiple cell types, including monocytes and osteoblasts
(Mori et al., 2011; Tosato and Jones, 1990).
Alternatively, because cathepsin B activity is important in the
trafficking of TNF-a-containing vesicles to the surface of macro-
phages (Ha et al., 2008), TNF-amay be one of the critical factors
mediating chemoprotection, either directly through NF-kb acti-
vation (Li and Sethi, 2010), or indirectly through induced IL-6
expression and subsequent STAT3 activation (Mori et al.,
2011). Macrophages can be a critical source of TNF-a in vivo,
as it has recently been demonstrated that macrophage-derived
TNF-a imparts resistance to MAPK inhibitors in melanoma
through NF-kb-dependent expression of microphthalmia tran-
scription factor (Smith et al., 2014). Further research is warranted
to determine whether macrophages indeed mediate resistance
to cytotoxic therapies via these pathways and to extend these
finding to other targeted therapeutics because with the com-plexities of TNF-a and NF-kb in cancer development/growth,
the efficacy of targeting these pathwaysmay be context-specific
(Balkwill, 2009).
Macrophages and Tumor Angiogenesis
Macrophages are well described regulators of tumor angiogen-
esis, with supporting evidence derived from both clinical and
experimental studies (Murdoch et al., 2008; Ruffell et al.,
2012a) in which much of their capability is associated with
vascular endothelial growth factor (VEGF) signaling. This in-
cludes macrophage production of VEGF-A (Lin et al., 2007;
Stockmann et al., 2008), production of VEGF homologs such
as placental growth factor (Fischer et al., 2007; Rolny et al.,
2011), enhancement of VEGF-A bioavailability through matrix
metalloproteinase (MMP)-9 activity (Bergers et al., 2000; Du
et al., 2008; Giraudo et al., 2004; Nakasone et al., 2012), and in-
duction of VEGF-A production by endothelial cells via WNT7B
expression (Yeo et al., 2014). VEGF-A drives the formation of
abnormal vasculature in tumors, consisting of excessive branch-
ing, dead-end vessels, and vessel leakiness, that, together,
impact tumor hemodynamics and drug delivery (Heldin et al.,
2004; Tre´dan et al., 2007). VEGF antagonists induce vascular
normalization (Greenberg et al., 2008; Jain, 2005), and several
studies have reported increased uptake of chemotherapeutics
associated with this process, likely because of reduced vessel
leakiness and interstitial fluid pressure (Chauhan et al., 2012;
Tong et al., 2004; Turley et al., 2012). Although macrophages
are not necessarily a dominant source of VEGF-A in all tumor tis-
sues, specific deletion of VEGF-A in macrophages via lysozyme
Mpromoter-driven Cre recombinase revealed their role in driving
abnormal vascular phenotypes in tumors (Stockmann et al.,
2008). Importantly, similar to the use of VEGF antagonists, tu-
mors in these mice were more sensitive to chemotherapy,
although, unexpectedly, they also grew at a faster rate because
of improved tissue perfusion and reduced hypoxia in the
absence of therapeutic intervention (Stockmann et al., 2008).
Although CSF-1 neutralization enhances the response to
chemotherapy in mammary carcinomas (DeNardo et al., 2011),
this is not due to the increased delivery of chemotherapeutic
agents, at least for small molecules such as paclitaxel and doxo-
rubicin (Ruffell et al., 2014). Why then does macrophage deple-
tion not phenocopy specific VEGF-A inhibition? One possible
explanation is that blockade of the CSF-1/CSF-1R pathway
only partially depletes macrophages in tumors, with macro-
phages surrounding the remaining vasculature (DeNardo et al.,
2011; Pyonteck et al., 2012; Ruffell et al., 2014). This residual
subset has not been analyzed in detail, but at least a portion of
the remaining cells are composed of Tie2+ macrophages
(Mitchem et al., 2013) associated with vascular programming
that are important mediators of tumor angiogenesis (De Palma
et al., 2005; Mazzieri et al., 2011). Although CSF-1 neutralization
could functionally impair the angiogenic potential of Tie2+ mono-
cytes (Forget et al., 2014), neutralizing angiopoietin-2, the ligand
for Tie2, inhibits the growth of mammary carcinomas (Mazzieri
et al., 2011), a phenotype not observed following therapeutic in-
hibition of CSF-1 or CSF-1R, and exhibits efficacy in xenograft
models when used in combination with chemotherapy or VEGF
antagonists (Brown et al., 2010). Interfering with Tie2+ macro-
phage recruitment via CXCR4 blockade also enhances the ef-
fects of the vasculature-disrupting agent CA-4-P (WelfordCancer Cell 27, April 13, 2015 ª2015 Elsevier Inc. 465
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mor growth in the context of VEGF/VEGFR inhibition (Priceman
et al., 2010; Zeisberger et al., 2006). Although Tie2 is also ex-
pressed by endothelial cells and pericytes (De Palma et al.,
2005), and, therefore, the results with angiopoietin-2 neutraliza-
tion cannot be entirely ascribed to the role of Tie2 expression by
macrophages in regulating vascular architecture (Mazzieri et al.,
2011), it would be interesting to evaluate combination angiopoie-
tin-2 and CSF-1R-blockade for synergistic efficacy.
Macrophages as Mediators of Immune Suppression
In murine tumormodels, macrophages contain immunosuppres-
sive transcriptional profiles (Biswas et al., 2006; Ojalvo et al.,
2009) and, accordingly, can directly suppress CD8+ T cell prolif-
eration in vitro (DeNardo et al., 2011; Doedens et al., 2010; Mo-
vahedi et al., 2010; Ruffell et al., 2014). Based on macrophage
expression of CD163, CD204, and CD206 in human tumors, it
is presumed that macrophages will exhibit similar profiles,
although this has yet to be evaluated in cells isolated directly
from tumors. That said, CD14+ myeloid cells from hepatocellular
and ovarian carcinomas suppress autologous T cell proliferation
and IFN-g expression in vitro and nullify anti-tumor T cell activity
during in vivo adoptive transfer experiments (Kryczek et al.,
2006; Kuang et al., 2009).
In mouse models, T cell suppression by immature myeloid
cells is typically linked to nutrient depletion via the metabolism
of L-arginine or production of free radicals (Gabrilovich and Na-
garaj, 2009). However, although hypoxia promotes macro-
phage-suppressive activity via expression of arginase-1 (Doe-
dens et al., 2010) and thyioglycollate-induced peritoneal
macrophages suppress T cell proliferation through L-arginine
depletion (Rodriguez et al., 2003), inhibition of arginase activity
does not blunt in vitro suppressive functions of tumor macro-
phages (Movahedi et al., 2010). This seems to be the case
even for MHCIILO macrophages associated with hypoxic areas
of tumors. To date, only inhibition of inducible nitric oxide syn-
thase (NOS) has been reported to reduce suppression by tumor
macrophages isolated from subcutaneously implanted lung car-
cinomas (Movahedi et al., 2010). Whether macrophages directly
suppress T cell activity in vivo remains compelling, albeit specu-
lative, but one role may simply be to overwhelm T cells with non-
productive interactions (Broz et al., 2014).
In humans, there is no evidence for a role of nutrient depletion
in mediating immune suppression by macrophages because
macrophages conditioned by ovarian carcinoma ascites sup-
press T cell proliferation independent of arginase and NOS activ-
ity (Kryczek et al., 2006). Instead, macrophages directly sup-
press T cell responses through programmed death ligand 1
(PD-L1) in hepatocellular carcinoma (Kuang et al., 2009) and
B7-H4 in ovarian carcinoma (Kryczek et al., 2006). This is
perhaps fortuitous because immune checkpoint blockade is
therapeutically more attractive (Pardoll, 2012), with monoclonal
antibodies against PD-1, PD-L1, and PD-L2 all in clinical trials.
Notably, the response rates in the PD-1/PD-L1 trials relate, at
least partially, to PD-L1 expression in tumor stroma (Herbst
et al., 2014; Tumeh et al., 2014), consistent with a role for mac-
rophages and/or other stromal cells in blocking anti-tumor
T cell responses. Could macrophage targeting enhance check-
point blockade therapy? At least one study to date has reported
this using an orthotopic implant model of PDAC, with CSF-1R in-466 Cancer Cell 27, April 13, 2015 ª2015 Elsevier Inc.hibition providing additive efficacy to either PD-1 or cytotoxic T
lymphocyte-associated protein 4 (CTLA-4) blockade in combi-
nation with gemcitabine (Zhu et al., 2014). Importantly, CSF-1R
inhibition also enhanced the response to combined PD-1/
CTLA-4 blockade in the absence of chemotherapy (Zhu et al.,
2014). Therefore, it would not be surprising for CSF-1R antago-
nists to be combined with checkpoint blockade antibodies in
future clinical trials (e.g., clinical trial NCT02323191).
Rather than directly suppressing anti-tumor T cell responses,
macrophages may also regulate the immune microenvironment
so that T cell responses are controlled indirectly through an inter-
mediate cell type, as first suggested in human ovarian carcinoma
with regulatory T (TReg) cell recruitment via CCL22 (Curiel et al.,
2004). In vitro, TReg cells induce IL-6 and IL-10 expression by
macrophages, leading to autocrine upregulation of B7-H4 and
a suppressive phenotype (Kryczek et al., 2006, 2007). Macro-
phages are also a key source of IL-10 in murine mammary carci-
nomas, but, in this system, macrophages do not express detect-
able levels of B7-H4 (B.R. and L.M.C., unpublished data), and
IL-10 was not a significant mediator of macrophage polarization
or suppressive function (Ruffell et al., 2014). Instead, in mam-
mary carcinomas exposed to paclitaxel, macrophage IL-10 sup-
presses the capacity of dendritic cells to express IL-12, thereby
blocking productive cytotoxic CD8+ T cell responses (Ruffell
et al., 2014). An increased understanding of interactions be-
tween macrophages and other immune cells in tumor microenvi-
ronments and deconstruction of the molecular pathways under-
lying these interactions will undoubtedly provide additional
therapeutic targets to fine-tune an immune response during
therapy.
Macrophages and Metastasis
From local invasion, intravasation into vessels, and extravasa-
tion at peripheral sites, macrophages (or their monocyte precur-
sors) have been implicated as regulators of all stages of the met-
astatic process, often through positive feedback pathways
involving CCL2 and/or CSF-1 (Joyce and Pollard, 2009). Studies
with human tissues have also demonstrated a relationship be-
tween epithelial-mesenchymal transition and macrophage
expression of CCL18, for which there is no murine homolog
(Meng et al., 2015; Su et al., 2014). Preclinical mouse models
of tumor development (mammary, pancreas, glioblastoma,
etc.) in which macrophages have either been depleted (albeit
not completely) or reprogrammed exhibit a diminished metasta-
tic burden in end-stage mice (DeNardo et al., 2009, 2011; Go-
cheva et al., 2010; Lin et al., 2001; Qian et al., 2009; Rolny
et al., 2011; Shree et al., 2011; Welm et al., 2007; Zabuawala
et al., 2010). Mechanistically, however, direct evidence for a
pro-metastatic role is largely derived from directed migration of
neoplastic cells in response to molecules secreted by macro-
phages (DeNardo et al., 2009; Mizutani et al., 2009; Qian et al.,
2009). The combined impact of these studies has been inter-
preted to indicate that therapies targetingmacrophage presence
and/or polarization would ameliorate metastasis in late-stage
cancer patients. The fact thatmalignant cells likely already reside
in secondary metastatic niches long before the clinical presenta-
tion of malignant primary disease (Valastyan and Weinberg,
2011) mandates that this therapeutic approach be evaluated
carefully. A recent evaluation of preclinical mammary carcinoma
metastasis models with CCL2-neutralizing antibodies revealed
Figure 3. Macrophage Function in the Tumor Microenvironment
(A) Macrophage expression of IL-6 and TNF-a promotes survival signaling in neoplastic cells and resistance to chemotherapy and targeted agents. The
expression of survival factors is dependent upon the protease activity of cathepsin B and/or S.
(B) Neoplastic cell invasion of ectopic tissue can be promoted through the directed release of cytokines/chemokines such as epidermal growth factor (EGF) and
CCL18 or through protease-dependent extracellular matrix (ECM) remodeling that may directly affect neoplastic migration or increase chemoattractant
bioavailability. EGF expression is driven by signaling through the CSF-1R via neoplastic cell production of CSF-1 as well as T cell-derived IL-4 (not shown).
(C) Macrophages directly promote angiogenesis via production of VEGFA and other angiogenic factors and can enhance VEGFA expression by endothelial cells
throughWNT7B. A subset ofmacrophages expressing the Tie2 receptor is recruited to the vasculature bymural cell/pericyte expression of ANG2 and is important
in regulating vascular structure.
(D) Direct suppression of a cytotoxic T cell (CTL) response can occur via expression of B7 family ligands (PD-L1, B7-H4). Indirect suppression may occur through
release of IL-10 or recruitment of IL-10-expressing TRegs via CCL22, whereby IL-10 suppresses the capacity of dendritic cells to produce IL-12 and promote a
TH1/CTL anti-tumor immune response.
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CCL2, although limiting early metastatic processes, promoted
metastasis following the cessation of therapy by enhancing the
recruitment of monocytes to micrometastatic lesions (Bonapace
et al., 2014). Therapies targeting the stromal compartment of pri-
mary tumors may also prove ineffective at treating metastasis if
the pathways regulating the targeted process differ between the
tissue of origin and the metastatic site. As a possible example of
this, IL-34 mediates the development of Langerhans cells and
microglia through CSF-1R (Wang et al., 2012), whereas CSF-
1R signaling is mediated in most tissues by CSF-1 (Pollard,
2009). The development of macrophage-directed therapeutics
aiming to minimize or eradicate metastasis will, therefore, first
require the identification of pathways that drive neoplastic cell
survival, proliferation, angiogenesis, and immune suppression
in ectopic sites. Some progress has been made in the lung,
where both VEGF-A and angiopoietin-2 appear to be important
for angiogenesis in metastatic tumors derived from mammary
carcinomas (Bonapace et al., 2014; Mazzieri et al., 2011). How-
ever, as mentioned, this may not be directly linked to macro-
phage function. Interestingly, CSF-1R inhibition reverses the
effects observed following cessation of CCL2 neutralization (Bo-
napace et al., 2014) even thoughCSF-1R inhibition does not alter
the number of macrophages in lungs (Strachan et al., 2013). This
could hint at a possible role for CSF-1R signaling in mediating
macrophage polarization in metastatic lungs, similar to the ob-
servations in glioblastoma multiforme (Pyonteck et al., 2013).Nevertheless, it remains uncertain whether macrophages are
important in mediating therapeutic resistance at metastatic sites
or even the degree to which they are involved in mediating met-
astatic outgrowth. Because the majority of patients succumb
to metastatic disease, this is an urgent area of research that
has been largely unexplored, in part because of experimental
obstacles such maintaining mice with spontaneously metasta-
sizing tumors where primary tumor burden limits the duration
of study.
Macrophages as Therapeutic Targets
Based on compelling preclinical data from numerous labora-
tories indicating that macrophage presence and/or activity are
malleable in vivo (Figure 3), clinical studies are now ongoing in
several solid tumor types where macrophages are being tar-
geted via CSF-1R inhibitors or by blocking monoclonal anti-
bodies (Table 1). Although a goal of these clinical studies is to
reduce the presence of tumor-associated macrophages, based
on preclinical and clinical studies, we anticipate that not all mac-
rophages will be eradicated. The hope is, however, that those re-
maining will be reprogrammed toward an anti-tumor phenotypic
state where they would support T cell responses and, together
with cytotoxic therapy, limit ongoing tumor growth. CSF-1R an-
tagonists appear well tolerated as single agents in both pre-clin-
ical and clinical studies (Radi et al., 2011; Ries et al., 2014; Ruffell
et al., 2014), but because significant macrophage depletion in
the colon and liver is observed in nonhuman primates, toxicityCancer Cell 27, April 13, 2015 ª2015 Elsevier Inc. 467
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ward. It should also be noted that although increased CSF-1
serum concentrations resulting from the use of CSF-1R antago-
nists (Ries et al., 2014) are an excellent biomarker to evaluate on-
target efficacy, recent findings with CCL2 inhibition (Bonapace
et al., 2014) indicate that recurrence or exacerbation of disease
is a possibility after therapy cessation. These potential issues will
need to be incorporated into the design of clinical studies for
appropriate drug combinations and patient monitoring.
Blocking macrophage recruitment into tumors (DeNardo et al.,
2011; Shiao et al., 2015), pro-tumor polarization (Affara et al.,
2014; Pyonteck et al., 2013; Shiao et al., 2015), effector function
(Ruffell et al., 2014; Shree et al., 2011), or directly promoting
macrophage activation (Beatty et al., 2011) have all been used
successfully in preclinical models to enhance the response to
cytotoxic therapy. The question remains which of these ap-
proaches (Table 1) will be most efficacious when combined with
cytotoxic, targeted, or immune checkpoint blockade therapy. At
least in a murine model of squamous cell carcinogenesis, repola-
rizing macrophages was more effective than blocking recruit-
ment, and, in fact, repolarized macrophages were necessary for
recruitment of CD8+ T cells via CCR5 during paclitaxel chemo-
therapy (Affara et al., 2014). For this reason, going forward, it will
be critical to understand whether depletion, or instead repolariza-
tion, is the best therapeutic approach to accompany combination
therapy, for which tumor types, and at which stage of tumor
progression (primary or metastatic disease). Multiple agents tar-
getingTH2cytokines and their receptorshavegonebeyondphase
II clinical trials, with demonstrated efficacy in autoimmune disor-
ders and acceptable safety profiles (Beck et al., 2014; Corren
et al., 2011; Danese et al., 2015). Although none of these com-
pounds have been re-directed toward therapy in solid tumors,
we have found recently that targeting this pathway (IL-4, IL-13,
IL-4Ra) improves the response to cytotoxic therapy (Shiao et al.,
2015).
One lesson learned from results comparing efficacy of immu-
notherapy in mice bearing orthotopic versus subcutaneously
implanted tumors is that the latter exhibit enhanced sensitivity
(Devaud et al., 2014), indicating that context matters. In light of
these findings and given the dearth of late-stage metastatic
studies, it will be important to be mindful of the fact that a one
size fits all approach, although attractive, may not be realistic
as we strive to translate preclinical findings to the clinic. A major
question to address regarding these preclinical and clinical
studies with either macrophage depletion or reprogramming ap-
proaches will be to evaluate the durability of resultant anti-tumor
immune responses formed against the tumor. Along these lines,
evaluating patients longitudinally for indicators of T cell function
or T cell receptor diversity could reveal an important diagnostic
opportunity to indicate when the addition of combination ther-
apy, e.g., immune checkpoint or anti-tumor vaccine, might be
beneficial to the patient.
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